{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T15:28:26Z","timestamp":1779118106284,"version":"3.51.4"},"reference-count":40,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2006,6,1]],"date-time":"2006-06-01T00:00:00Z","timestamp":1149120000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2006,6,1]],"date-time":"2006-06-01T00:00:00Z","timestamp":1149120000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["jpet.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Pharmacology and Experimental Therapeutics"],"published-print":{"date-parts":[[2006,6]]},"DOI":"10.1124\/jpet.106.101949","type":"journal-article","created":{"date-parts":[[2006,3,2]],"date-time":"2006-03-02T01:45:19Z","timestamp":1141263919000},"page":"1188-1199","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":73,"title":["Potent Antitumor Activity of a Novel Cationic Pyridinium-Ceramide Alone or in Combination with Gemcitabine against Human Head and Neck Squamous Cell Carcinomas in Vitro and in Vivo"],"prefix":"10.1016","volume":"317","author":[{"given":"Can E.","family":"Senkal","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Suriyan","family":"Ponnusamy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael J.","family":"Rossi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kamala","family":"Sundararaj","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zdzislaw","family":"Szulc","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jacek","family":"Bielawski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alicja","family":"Bielawska","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mario","family":"Meyer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bengu","family":"Cobanoglu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Serap","family":"Koybasi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Debajyoti","family":"Sinha","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Terry A.","family":"Day","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lina M.","family":"Obeid","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yusuf A.","family":"Hannun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Besim","family":"Ogretmen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1124\/jpet.106.101949_bib1","doi-asserted-by":"crossref","unstructured":"Aguilar-Ponce J, Granados-Garcia M, Villavicencio V, Poitevin-Chacon A, Green D, Duenas-Gonzalez A, Herrera-Gomez A, Luna-Ortiz K, Alvarado A, Martinez-Said H, et al. (2004) Phase II trial of gemcitabine concurrent with radiation for locally advanced squamous cell carcinoma of the head and neck. Ann Oncol 15: 301\u2013306.","DOI":"10.1093\/annonc\/mdh071"},{"key":"10.1124\/jpet.106.101949_bib2","unstructured":"Airoldi M, Cattel L, Cortesina G, Giordano C, Passera R, Pedani F, Novello S, Bumma C, and Gabriele P (2003) Gemcitabine and vinorelbine in recurrent head and neck cancer: pharmacokinetics and clinical results. Anticancer Res 23: 2845\u20132852."},{"key":"10.1124\/jpet.106.101949_bib3","doi-asserted-by":"crossref","unstructured":"Argiris A, Li Y, Murphy BA, Langer CJ, and Forastiere AA (2004) Outcome of elderly patients with recurrent or metastatic head and neck cancer treated with cisplatin-based chemotherapy. J Clin Oncol 22: 262\u2013268.","DOI":"10.1200\/JCO.2004.08.039"},{"key":"10.1124\/jpet.106.101949_bib4","doi-asserted-by":"crossref","unstructured":"Bieberich E, Kawaguchi T, and Yu RK (2000) N-Acylated serinol is a novel ceramide mimic inducing apoptosis in neuroblastoma cells. J Biol Chem 275: 177\u2013181.","DOI":"10.1074\/jbc.275.1.177"},{"key":"10.1124\/jpet.106.101949_bib5","doi-asserted-by":"crossref","unstructured":"Bradford CR, Zhu S, Ogawa H, Ogawa T, Ubell M, Narayan A, Johnson G, Wolf GT, Fisher SG, and Carey TE (2003) p53 mutation correlates with cisplatin sensitivity in head and neck squamous cell carcinoma lines. Head Neck 25: 654\u2013661.","DOI":"10.1002\/hed.10274"},{"key":"10.1124\/jpet.106.101949_bib6","doi-asserted-by":"crossref","unstructured":"Bruce IA, Slevin NJ, Homer JJ, McGown AT, and Ward TH (2005) Synergistic effects of imatinib (STI 571) in combination with chemotherapeutic drugs in head and neck cancer. Anticancer Drugs 16: 719\u2013726.","DOI":"10.1097\/01.cad.0000168392.04676.bb"},{"key":"10.1124\/jpet.106.101949_bib7","doi-asserted-by":"crossref","unstructured":"Cohen EE, Lingen MW, and Vokes EE (2004) The expanding role of systemic therapy in head and neck cancer. J Clin Oncol 22: 1743\u20131752.","DOI":"10.1200\/JCO.2004.06.147"},{"key":"10.1124\/jpet.106.101949_bib8","unstructured":"Crawford KW, Bittman R, Chun J, Byun HS, and Bowen WD (2003) Novel ceramide analogs display selective cytotoxicity in drug-resistant breast tumor cell lines compared to normal breast epithelial cells. Cell Mol Biol 49: 1017\u20131023."},{"key":"10.1124\/jpet.106.101949_bib9","doi-asserted-by":"crossref","unstructured":"Don AS and Hogg PJ (2004) Mitochondria as cancer drug targets. Trends Mol Med 10: 372\u2013378.","DOI":"10.1016\/j.molmed.2004.06.005"},{"key":"10.1124\/jpet.106.101949_bib10","doi-asserted-by":"crossref","unstructured":"Fabricius EM, Gurr U, and Wildner GP (2002) Telomerase activity levels in the surgical margin and tumour distant tissue of the squamous cell carcinoma of the head and neck. Anal Cell Pathol 24: 25\u201339.","DOI":"10.1155\/2002\/452527"},{"key":"10.1124\/jpet.106.101949_bib11","doi-asserted-by":"crossref","unstructured":"Fantin VR and Leder P (2004) F16, a mitochondriotoxic compound, triggers apoptosis or necrosis depending on the genetic background of the target carcinoma cell. Cancer Res 64: 329\u2013336.","DOI":"10.1158\/0008-5472.CAN-03-0899"},{"key":"10.1124\/jpet.106.101949_bib12","doi-asserted-by":"crossref","unstructured":"Harrington KJ, Lewanski C, Northcote AD, Whittaker J, Peters AM, Vile RG, and Stewart JS (2001) Phase II study of pegylated liposomal doxorubicin (Caelyx) as induction chemotherapy for patients with squamous cell cancer of the head and neck. Eur J Cancer 37: 2015\u20132022.","DOI":"10.1016\/S0959-8049(01)00216-7"},{"key":"10.1124\/jpet.106.101949_bib13","unstructured":"Her C (2001) Nasopharyngeal cancer and the Southeast Asian patient. Am Fam Physician 63: 1776\u20131782."},{"key":"10.1124\/jpet.106.101949_bib14","doi-asserted-by":"crossref","unstructured":"Inaba M, Kobayashi T, Tashiro T, Sakurai Y, Maruo K, Ohnishi Y, Ueyama Y, and Nomura T (1989) Evaluation of antitumor activity in a human breast tumor\/nude mouse model with a special emphasis on treatment dose. Cancer 64: 1577\u20131582.","DOI":"10.1002\/1097-0142(19891015)64:8<1577::AID-CNCR2820640803>3.0.CO;2-I"},{"key":"10.1124\/jpet.106.101949_bib15","doi-asserted-by":"crossref","unstructured":"Jemal A, Murray T, Ward E, Samuels A, Tiwari RC, Ghafoor A, Feuer EJ, and Thun MJ (2004) Cancer statistics, 2004. CA Cancer J Clin 54: 8\u201329.","DOI":"10.3322\/canjclin.54.1.8"},{"key":"10.1124\/jpet.106.101949_bib16","doi-asserted-by":"crossref","unstructured":"Jiang Y, Wei YQ, Luo F, Zou LQ, Liu JY, Peng F, Huang MJ, and He QM (2005) Gemcitabine and cisplatin in advanced nasopharyngeal carcinoma: a pilot study. Cancer Investig 23: 123\u2013128.","DOI":"10.1081\/CNV-200050438"},{"key":"10.1124\/jpet.106.101949_bib17","doi-asserted-by":"crossref","unstructured":"Kim JH, Park SM, Kang MR, Oh SY, Lee TH, Muller MT, and Chung IK (2005) Ubiquitin ligase MKRN1 modulates telomere length homeostasis through a proteolysis of hTERT. Genes Dev 19: 776\u2013781.","DOI":"10.1101\/gad.1289405"},{"key":"10.1124\/jpet.106.101949_bib18","doi-asserted-by":"crossref","unstructured":"Koscielny S, Eggeling F, Dahse R, and Fiedler W (2004) The influence of reactivation of the telomerase in tumour tissue on the prognosis of squamous cell carcinomas in the head and neck. J Oral Pathol Med 33: 538\u2013542.","DOI":"10.1111\/j.1600-0714.2004.00232.x"},{"key":"10.1124\/jpet.106.101949_bib19","doi-asserted-by":"crossref","unstructured":"Koybasi S, Senkal CE, Sundararaj K, Spassieva S, Bielawski J, Osta W, Day TA, Jiang JC, Jazwinski SM, Hannun YA, et al. (2004) Defects in cell growth regulation by C18:0-ceramide and longevity assurance gene 1 in human head and neck squamous cell carcinomas. J Biol Chem 279: 44311\u201344319.","DOI":"10.1074\/jbc.M406920200"},{"key":"10.1124\/jpet.106.101949_bib20","doi-asserted-by":"crossref","unstructured":"Kroep JR, Peters GJ, van Moorsel CJ, Catik A, Vermorken JB, Pinedo HM, and van Groeningen CJ (1999) Gemcitabine-cisplatin: a schedule finding study. Ann Oncol 10: 1503\u20131510.","DOI":"10.1023\/A:1008339425708"},{"key":"10.1124\/jpet.106.101949_bib21","doi-asserted-by":"crossref","unstructured":"Makino M, Shoji H, Takemoto D, Honboh T, Nakamura S, Kurayoshi K, and Kaibara N (2001) Comparative study between daily and 5-days-a-week administration of 5-fluorouracil chemotherapy in mice: determining the superior regimen. Cancer Chemother Pharmacol 48: 370\u2013374.","DOI":"10.1007\/s002800100359"},{"key":"10.1124\/jpet.106.101949_bib22","doi-asserted-by":"crossref","unstructured":"Modica-Napolitano JS and Aprille JR (2001) Delocalized lipophilic cations selectively target the mitochondria of carcinoma cells. Adv Drug Deliv Rev 49: 63\u201370.","DOI":"10.1016\/S0169-409X(01)00125-9"},{"key":"10.1124\/jpet.106.101949_bib23","doi-asserted-by":"crossref","unstructured":"Novgorodov SA, Szulc ZM, Luberto C, Jones JA, Bielawski J, Bielawska A, Hannun YA, and Obeid LM (2005) Positively charged ceramide is a potent inducer of mitochondrial permeabilization. J Biol Chem 280: 16096\u201316105.","DOI":"10.1074\/jbc.M411707200"},{"key":"10.1124\/jpet.106.101949_bib24","doi-asserted-by":"crossref","unstructured":"Ogretmen B and Hannun YA (2004) Biologically active sphingolipids in cancer pathogenesis and treatment. Nat Rev Cancer 4: 604\u2013616.","DOI":"10.1038\/nrc1411"},{"key":"10.1124\/jpet.106.101949_bib25","doi-asserted-by":"crossref","unstructured":"Ogretmen B, Kraveka JM, Schady D, Usta J, Hannun YA, and Obeid LM (2001) Molecular mechanisms of ceramide-mediated telomerase inhibition in the A549 human lung adenocarcinoma cell line. J Biol Chem 276: 32506\u201332514.","DOI":"10.1074\/jbc.M101350200"},{"key":"10.1124\/jpet.106.101949_bib26","doi-asserted-by":"crossref","unstructured":"Patel MM, Parekh LJ, Jha FP, Sainger RN, Patel JB, Patel DD, Shah PM, and Patel PS (2002) Clinical usefulness of telomerase activation and telomere length in head and neck cancer. Head Neck 24: 1060\u20131067.","DOI":"10.1002\/hed.10169"},{"key":"10.1124\/jpet.106.101949_bib27","doi-asserted-by":"crossref","unstructured":"Pietruck F and Ullrich KJ (1995) Transport interactions of different organic cations during their excretion by the intact rat kidney. Kidney Int 47: 1647\u20131657.","DOI":"10.1038\/ki.1995.229"},{"key":"10.1124\/jpet.106.101949_bib28","doi-asserted-by":"crossref","unstructured":"Prevost A, Merol JC, Aime P, Moutel K, Roger-Liautaud F, Nasca S, Legros M, and Coninx P (2005) A randomized trial between two neoadjuvant chemotherapy protocols: CDDP + 5-FU versus CDDP + VP16 in advanced cancer of the head and neck. Oncol Rep 14: 771\u2013776.","DOI":"10.3892\/or.14.3.771"},{"key":"10.1124\/jpet.106.101949_bib29","doi-asserted-by":"crossref","unstructured":"Rossi MJ, Sundararaj K, Koybasi S, Phillips MS, Szulc ZM, Bielawska A, Day TA, Obeid LM, Hannun YA, and Ogretmen B (2005) Inhibition of growth and telomerase activity by novel cationic ceramide analogs with high solubility in human head and neck squamous cell carcinoma cells. Otolaryngol Head Neck Surg 132: 55\u201362.","DOI":"10.1016\/j.otohns.2004.08.015"},{"key":"10.1124\/jpet.106.101949_bib30","doi-asserted-by":"crossref","unstructured":"Rotem R, Heyfets A, Fingrut O, Blickstein D, and Shaklai M (2005) Jasmonates: novel anticancer agents acting directly and selectively on human cancer cell mitochondria. Cancer Res 65: 1984\u20131993.","DOI":"10.1158\/0008-5472.CAN-04-3091"},{"key":"10.1124\/jpet.106.101949_bib31","doi-asserted-by":"crossref","unstructured":"Shabbits JA and Mayer LD (2003) Intracellular delivery of ceramide lipids via liposomes enhances apoptosis in vitro. Biochim Biophys Acta 1612: 98\u2013106.","DOI":"10.1016\/S0005-2736(03)00108-1"},{"key":"10.1124\/jpet.106.101949_bib32","doi-asserted-by":"crossref","unstructured":"Steel GG and Peckham MJ (1979) Exploitable mechanisms in combined radiotherapy-chemotherapy: the concept of additivity. Int J Radiat Oncol Biol Phys 5: 85\u201393.","DOI":"10.1016\/0360-3016(79)90044-0"},{"key":"10.1124\/jpet.106.101949_bib33","doi-asserted-by":"crossref","unstructured":"Stover T and Kester M (2003) Liposomal delivery enhances short-chain ceramide-induced apoptosis of breast cancer cells. J Pharmacol Exp Ther 307: 468\u2013475.","DOI":"10.1124\/jpet.103.054056"},{"key":"10.1124\/jpet.106.101949_bib34","doi-asserted-by":"crossref","unstructured":"Stover TC, Sharma A, Robertson GP, and Kester M (2005) Systemic delivery of liposomal short-chain ceramide limits solid tumor growth in murine models of breast adenocarcinoma. Clin Cancer Res 11: 3465\u20133474.","DOI":"10.1158\/1078-0432.CCR-04-1770"},{"key":"10.1124\/jpet.106.101949_bib35","doi-asserted-by":"crossref","unstructured":"Struckhoff AP, Bittman R, Burow ME, Clejan S, Elliott S, Hammond T, Tang Y, and Beckman BS (2004) Novel ceramide analogs as potential chemotherapeutic agents in breast cancer. J Pharmacol Exp Ther 309: 523\u2013532.","DOI":"10.1124\/jpet.103.062760"},{"key":"10.1124\/jpet.106.101949_bib36","doi-asserted-by":"crossref","unstructured":"Sundararaj KP, Wood RE, Ponnusamy S, Salas AM, Szulc Z, Bielawska A, Obeid LM, Hannun YA, and Ogretmen B (2004) Rapid shortening of telomere length in response to ceramide involves the inhibition of telomere binding activity of nuclear glyceraldehyde-3-phosphate dehydrogenase. J Biol Chem 279: 6152\u20136162.","DOI":"10.1074\/jbc.M310549200"},{"key":"10.1124\/jpet.106.101949_bib37","doi-asserted-by":"crossref","unstructured":"Tao Z, Chen S, Wu Z, Xiao B, Liu J, and Hou W (2005) Targeted therapy of human laryngeal squamous cell carcinoma in vitro by antisense oligonucleotides directed against telomerase reverse transcriptase mRNA. J Laryngol Otol 119: 92\u201396.","DOI":"10.1258\/0022215053419943"},{"key":"10.1124\/jpet.106.101949_bib38","doi-asserted-by":"crossref","unstructured":"van Moorsel CJ, Pinedo HM, Veerman G, Vermorken JB, Postmus PE, and Peters GJ (1999) Scheduling of gemcitabine and cisplatin in Lewis lung tumour bearing mice. Eur J Cancer 35: 808\u2013814.","DOI":"10.1016\/S0959-8049(99)00004-0"},{"key":"10.1124\/jpet.106.101949_bib39","doi-asserted-by":"crossref","unstructured":"Veerman G, Ruiz van Haperen VW, Vermorken JB, Noordhuis P, Braakhuis BJ, Pinedo HM, and Peters GJ (1996) Antitumor activity of prolonged as compared with bolus administration os 2\u2032,2\u2032-difluorodeoxycytidine in vivo against murine colon tumors. Cancer Chemother Pharmacol 38: 335\u2013342.","DOI":"10.1007\/s002800050492"},{"key":"10.1124\/jpet.106.101949_bib40","doi-asserted-by":"crossref","unstructured":"Wooten LG and Ogretmen B (2005) Sp1\/Sp3-dependent regulation of human telomerase reverse transcriptase promoter activity by the bioactive sphingolipid ceramide. J Biol Chem 280: 28867\u201328876.","DOI":"10.1074\/jbc.M413444200"}],"container-title":["The Journal of Pharmacology and Experimental Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022356524327223?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022356524327223?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1124\/jpet.106.101949","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,19]],"date-time":"2025-02-19T21:53:28Z","timestamp":1740002008000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022356524327223"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,6]]},"references-count":40,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2006,6]]}},"alternative-id":["S0022356524327223"],"URL":"https:\/\/doi.org\/10.1124\/jpet.106.101949","relation":{},"ISSN":["0022-3565"],"issn-type":[{"value":"0022-3565","type":"print"}],"subject":[],"published":{"date-parts":[[2006,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Potent Antitumor Activity of a Novel Cationic Pyridinium-Ceramide Alone or in Combination with Gemcitabine against Human Head and Neck Squamous Cell Carcinomas in Vitro and in Vivo","name":"articletitle","label":"Article Title"},{"value":"The Journal of Pharmacology and Experimental Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1124\/jpet.106.101949","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2006 The American Society for Pharmacology and Experimental Therapeutics","name":"copyright","label":"Copyright"}]}}